Mashup Score:20
UroToday# GU23
Mashup Score:7
VJOncologyIn this exclusive VJSession, join GU cancer experts Sophia Kamran (Massachusetts General Hospital and Harvard Medical School, Boston, MA), Himanshu Nagar (Weill Cornell Medicine...
-
Interested in radiotherapy for GU cancers? Catch up on the latest developments with @sophia_kamran @HimanshuNagarMD and @NehaVapiwala! Watch here 👉 https://t.co/5HRbbUN3TO #PCSM #BlcSM #KCSM @ASCO #RadOnc @ASTRO_org #GU23 https://t.co/5HRbbUN3TO - view on twitter
Mashup Score:5
channel.royalcast.comReal-World Evidence in Advanced Bladder Cancer - 15 hours
Mashup Score:5
...
-
Dear Colleagues @OncoAlert is collaborating with our friends at @mirrorsmed on this FREE (case) discussion on management of advanced #bladdercancer based on real world🌐data from #GU23 to take place on April 18, 2023 6⃣PM CET🇪🇺 1⃣2⃣ noon EST🇺🇸 Vote 🗳️& https://t.co/F3DhtveIc3… https://t.co/F3DhtveIc3… https://t.co/F3DhtveIc3… - view on twitter
Mashup Score:3
OncLiveTivozanib Plus Atezolizumab Under Investigation in Immunologically Cold Tumors - 6 days
Mashup Score:3
The safety and efficacy of the immune checkpoint inhibitor atezolizumab plus the VEGF TKI tivozanib is being investigated in patients with unresectable or metastatic...
-
Tivozanib Plus Atezolizumab Under Investigation in Immunologically Cold Tumors @UFMedicine @UFHealth @ASCO #pcsm #oncology #GU23 https://t.co/qhVEnIC3Ye - view on twitter
Treatment with the antibody-drug conjugate sacituzumab govitecan-hziy achieved an objective response rate of 32% in platinum-ineligible patients with metastatic urothelial cancer who experienced disease...
-
Sacituzumab Govitecan-hziy Achieves Response After Disease Progression on Immune Checkpoint Inhibitor in Metastatic Urothelial Cancer https://t.co/SbuxDBAqla #blcsm #bladdercancer #oncology #GU23 - view on twitter
The addition of the poly (ADP ribose) polymerase (PARP) inhibitor talazoparib to the androgen receptor signaling inhibitor enzalutamide achieved a statistically significant and clinically...
-
TALAPRO-2: Talazoparib Plus Enzalutamide Extends Radiographic Progression–Free Survival in Metastatic Castration-Resistant Prostate Cancer https://t.co/UKDRs2RiJW #GU23 #pcsm #prostatecancer #oncology - view on twitter
Mashup Score:1
Oncology Nursing NewsLeapman On Improving Genomic Testing Communication For Patients With Prostate Cancer - 3 days
Mashup Score:1
Michael S. Leapman, MD, MHS, highlights the need for clearer information regarding genomic testing for patients with prostate...
-
Leapman On Improving Genomic Testing Communication For Patients With Prostate Cancer Watch Here: https://t.co/uHYf3ChiKe #pcsm #GU23 #oncology #nursing @YaleCancer @mleapman https://t.co/uHYf3ChiKe - view on twitter
Michael S. Leapman, MD, MHS, highlights the need for clearer information regarding genomic testing for patients with prostate...
-
Tissue-based gene expression tests are used to assess disease aggressiveness and inform decisions during active surveillance, but little is known about how patients perceive these tests, says Michael Leapman, MD, MHS. #pcsm #GU23 @YaleCancer Watch here: https://t.co/jIZWC3xfvB https://t.co/jIZWC3xfvB - view on twitter
By Alice Goodman Posted: 3/23/2023 11:07:00 AM Last Updated: 3/23/2023 11:22:11 AM The addition of the androgen receptor inhibitor darolutamide to androgen-deprivation therapy and...
-
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer https://t.co/l48pIwfEru #pcsm #prostatecancer #GU23 #oncology - view on twitter
This phase III trial, however, did not meet statistical significance for its primary endpoint in the overall study population. The addition of abiraterone acetate...
-
FORMULA-509: Intensified Postoperative Regimen May Be of Benefit in Subset of High-Risk Prostate Cancer https://t.co/IMiWxKmn60 #pcsm #prostatecancer #oncology #GU23 - view on twitter
Kyle Rose joins Sam Chang in discussing his team’s findings regarding the impact of cell-free urinary DNA on non-muscle invasive bladder cancer patients. This...
Cell-free urinary DNA predictive impact on patients with non-muscle invasive #BladderCancer. @KyleRoseMD @MoffittNews joins @UroCancerMD @VUMC_Cancer to discuss his team's findings in this conversation on UroToday > https://t.co/BFgdhxROYS #GU23 @ASCO https://t.co/BFgdhxROYS - view on twitter